The Cancer Drugs Clinical Pipeline 2023​


​Release Date: Q3' 2023
Number of Candidates: 362

Synopsis: Often cited as one of the leading causes of death worldwide, cancer refers to a group of diseases that are characterized by unrestrained or unregulated growth of cells leading to the formation of malignant tumors that can invade other parts of the body and eventually impair normal functions. 

The prevalence of cancer is continuing to grow, with approximately 19.5 Million new cases globally each year. However, several immunotherapy and targeted treatments have significantly improved patient outcomes and survival rates. The market is ripe for future growth with several targeted therapies in late-stage development, such as PD-1/PD-L1 inhibitors and ADCs, as well as combination therapies countering tumor resistance. An innovative landscape awaits cancer treatment, driven by advancements in cell therapies like CAR-T and TCR for solid tumors, along with the emergence of "off-the-shelf" cellular therapy options.

As new drugs continue to revitalize the cancer treatment ecosystem, we expect the cancer drugs market to grow at a CAGR of 12.1% between 2023 and 2028, eventually accounting for nearly $369.5 Billion in revenue by 2028.

The Cancer drug development pipeline excel sheet features 362 candidates spanning 10 Therapeutic categories & 5 classifications in active development. 

For a Sample and Inquiries please contact info@snsintel.com

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 1250

Company Wide License (Single Site): USD 2000

Company Wide License (Global Site): USD 3000

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories: 
  • Candidate Name
  • Drug Developer(s)
  • Phase(s)
    • ​Phase I/II
    • Phase II
    • Phase II/III
    • Phase III
    • Pre-Clinical
    • Pre-Registration 
  • Therapeutic Category ​​
    • Blood Cancer
    • ​Breast Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Solid Tumors
    • Skin Cancer
    • Head & Neck Cancer
    • Gynecological Cancer
    • Multiple Indications
    • Others
  • Classification ​​
    • ​New Molecular Entity
    • New Indication(s)/Re-Formulation/ New Delivery Technology
    • Gene & Cell Therapies
    • Biosimilar
    • Cancer Vaccine